A phase II trial of irinotecan in patients with advanced or recurrent endometrial cancer and correlation with biomarker analysis.

Shin Nishio,Mototsugu Shimokawa,Kazuto Tasaki,Hiroki Nasu,Teruyuki Yoshimitsu,Ken Matsukuma,Atsumu Terada,Naotake Tsuda,Kouichiro Kawano,Kimio Ushijima

Gynecologic Oncology（2018）

引用 2|浏览23

暂无评分

摘要

•CPT-11 has a clinically significant response rate for endometrial cancer.•Clinical benefits and overall survival make it a promising treatment.•Adverse events are manageable and do not compromise treatment administration.

查看译文

关键词

Phase II clinical trial,Endometrial cancer,Irinotecan,Chemotherapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要